| Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ... Journal of Clinical Oncology 39 (21), 2375-2385, 2021 | 106 | 2021 |
| Temperate membrane-containing halophilic archaeal virus SNJ1 has a circular dsDNA genome identical to that of plasmid pHH205 Z Zhang, Y Liu, S Wang, D Yang, Y Cheng, J Hu, J Chen, Y Mei, P Shen, ... Virology 434 (2), 233-241, 2012 | 69 | 2012 |
| Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer H SM Wong, N Almana, J Choi, J Hu Annuals of surgical oncology, 2019 | 67* | 2019 |
| Margins in breast-conserving surgery after neoadjuvant therapy J Choi, A Laws, J Hu, W Barry, M Golshan, T King Annals of surgical oncology 25, 3541-3547, 2018 | 67 | 2018 |
| The impact of high-dose glucocorticoids on the outcome of immune checkpoint inhibitor-related thyroid disorders SMTLM Chanjuan Ma, F. Stephen Hodi, Anita Giobbie-Hurder, Xiaocheng Wang ... Cancer Immunology Research, 2019 | 47 | 2019 |
| Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases JP Leone, KE Emblem, M Weitz, RS Gelman, BP Schneider, ... Breast Cancer Research 22, 1-12, 2020 | 40 | 2020 |
| Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer MBRJ Yanan Kuang, Bilal Siddiqui, Jiani Hu, Matthew Pun, MacIntosh Cornwell ... npj Breast Cancer, 2018 | 38 | 2018 |
| A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases JP Leone, DG Duda, J Hu, WT Barry, L Trippa, ER Gerstner, RK Jain, ... Breast cancer research and treatment 179, 113-123, 2020 | 29 | 2020 |
| TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer … SM Tolaney, L Trippa, W Barry, J Hu, C Dang, D Yardley, S Isakoff, ... CANCER RESEARCH 80 (4), 2020 | 28 | 2020 |
| Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy TAK Alison Laws, Melissa E. Hughes, Jiani Hu, William T. Barry, Laura ... Annals of Surgical Oncology, 2019 | 28 | 2019 |
| Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). SM Tolaney, R Barroso-Sousa, T Keenan, L Trippa, J Hu, IMVD Luis, ... Journal of Clinical Oncology 37 (15_suppl), 1004-1004, 2019 | 26 | 2019 |
| Association of local therapy with quality-of-life outcomes in young women with breast cancer L Dominici, J Hu, Y Zheng, HJ Kim, TA King, KJ Ruddy, RM Tamimi, ... JAMA surgery 156 (10), e213758-e213758, 2021 | 23 | 2021 |
| Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors KT Do, C Manuszak, E Thrash, A Giobbie-Hurder, J Hu, S Kelland, ... Cancer Immunology, Immunotherapy 70, 2991-3000, 2021 | 23 | 2021 |
| Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy A Laws, K Anderson, J Hu, K McLean, L Novak, LS Dominici, F Nakhlis, ... Annals of surgical oncology 25 (12), 3548-3555, 2018 | 23 | 2018 |
| Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer TE Keenan, JL Guerriero, R Barroso-Sousa, T Li, T O’Meara, ... Nature Communications 12 (1), 5563, 2021 | 21 | 2021 |
| Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH)(TBCRC033: ATEMPT Trial) KJ Ruddy, Y Zheng, N Tayob, J Hu, CT Dang, DA Yardley, SJ Isakoff, ... Breast Cancer Research and Treatment 189 (1), 103-110, 2021 | 21 | 2021 |
| Abstract GS1-05: TBCRC 033: a randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2 … SM Tolaney, L Trippa, W Barry, J Hu, C Dang, D Yardley, S Isakoff, ... Cancer Research 80 (4_Supplement), GS1-05-GS1-05, 2020 | 20 | 2020 |
| Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series S Grossmith, A Nguyen, J Hu, JK Plichta, F Nakhlis, L Cutone, L Dominici, ... Annals of Surgical Oncology, 2018 | 19 | 2018 |
| The potential impact of AMAROS on the management of the axilla in patients with clinical T1-2N0 breast cancer undergoing primary total mastectomy M Moossdorff, F Nakhlis, J Hu, WT Barry, K Losk, C Haskett, ML Smidt, ... Annals of Surgical Oncology 25, 2612-2619, 2018 | 17 | 2018 |
| Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning HA Jacene, PJ DiPiro, J Bellon, J Hu, SC Cheng, L Warren, ... Breast Cancer Research and Treatment 181, 383-390, 2020 | 15 | 2020 |
William (Bill) BarryPrincipal Statistical Reseach Scientist, Rho, IncVerified email at rhoworld.com
